CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
about
Recent developments of protein kinase inhibitors as potential AD therapeuticsTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsGenotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cellsNeuroprotective strategies for traumatic brain injury: improving clinical translationScreening marine resources to find novel chemical inhibitors of disease-relevant protein kinasesCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsInhibition of E2F1/CDK1 pathway attenuates neuronal apoptosis in vitro and confers neuroprotection after spinal cord injury in vivoCDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction pointMolecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug designAftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease?Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury.What's New in Traumatic Brain Injury: Update on Tracking, Monitoring and TreatmentSynthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.Hydroxylated sclerosporin derivatives from the marine-derived fungus Cadophora malorum.CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials.Stachylines A-D from the sponge-derived fungus Stachylidium sp.Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanismPharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice.Marilones A-C, phthalides from the sponge-derived fungus Stachylidium spF-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stressCyclin Dependent Kinase 9 Inhibitors for Cancer TherapyDelayed expression of cell cycle proteins contributes to astroglial scar formation and chronic inflammation after rat spinal cord contusionHuman cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents.Protein kinase inhibitors: contributions from structure to clinical compounds.CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury.Functional genomics identify Birc5/survivin as a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Cyclin-dependent kinase inhibitors closer to market launch?Casein kinases as potential therapeutic targets.Inhibition of CDK5 Alleviates the Cardiac Phenotypes in Timothy Syndrome.Overview of CDK9 as a target in cancer research.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.Preliminary crystallographic analysis of the kinase domain of SAD-1, a protein essential for presynaptic differentiation in Caenorhabditis elegans.Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis.
P2860
Q21129481-781E8DEA-77B0-4263-A772-D5B851CF51AAQ26827580-473C6D11-ABC8-4B91-BFA8-7F3D6AA071DDQ26851196-DEFB2428-F471-4482-A3DA-31AC0EC9B18DQ27004018-E01BB06A-BAD3-4694-AE36-9BEB0FB68DAAQ27026168-E66E24F7-AF89-433A-981D-FBEB9FF45BB5Q27670943-3725D4A5-907D-48FC-AEC1-76C0617363DAQ28481548-F6986357-6ECA-4740-BDF6-C85ABA270EBEQ28533417-674BDCA6-BBFC-4340-8DE2-2FAD3AC302AAQ28533443-FF537B39-FE9E-457C-B865-56970A51A6E8Q28828789-607B736C-6107-4E78-9B34-E4E19D3C51FBQ30313935-39832665-75B9-41B8-B2FA-02B217057043Q30513085-45C1BB49-C416-4A9B-9AB6-A6C1E5DF29DDQ30959630-F272A78C-AFC3-4D6A-9F17-37973FAB66B4Q33752856-A8E2C4F7-ACDF-4934-A64E-01DB60490E0DQ33756044-DC4A924B-3297-4A52-8E0B-130CC054D449Q33864755-0311B5C9-1587-4E0E-B77C-7B86C9EA79C8Q34359688-F8F4E18E-439C-49B9-9711-61A15BB7A9C8Q34412771-C9B0EFEF-F571-4879-AC79-A9357B0A16A0Q34762071-FF9B4B5A-8A2D-4DDC-876F-020839259F0CQ34954019-515C5475-DE4B-4392-8856-72B91C4BF677Q35002296-3422BF03-9039-40D7-83CA-FD87B93E1684Q35657445-2A7AA615-CEBD-4009-8896-F423B3119436Q35865629-BE207C22-7351-4CA8-B8EC-7EC532FD6E4AQ36015334-B301CAEB-F093-4060-9292-3F507AC4EF54Q36136722-BA872CB6-3E4B-4F00-9DD0-95FA4130C918Q36196359-28430A3C-86B2-4E81-95A3-49110826E567Q37417742-D0947E74-DE91-4A1B-8AC2-2C1C807CC3BEQ37627776-D6AF4399-CA6C-4C50-9149-75CE3E55AB03Q37698908-1BD893F5-A267-4CF7-8A01-592BF07F6FBAQ38008733-3CC59E0D-628D-4B80-B9AF-0987C991AB35Q38100203-F7C37F6B-EDBD-4D22-A1C4-21C117DEC94CQ38632634-3344A228-571C-4AA5-8040-F53DCE177221Q38666952-526C3A17-3DE4-4D2B-A399-3D819C9E3F04Q38696353-3507B537-57A8-4EF7-98A8-9C6243FDE151Q38806786-F8A86105-19BC-48B7-A971-8B4D7CA11810Q38850709-67AECDD4-9D01-4FE3-A6A9-6386D82D9BE3Q38995743-CBD30FD1-5798-41D0-9138-69E8EF32AC66Q39508086-26491CC3-C4B8-45BF-A05C-A7AD6D828306Q39555976-2BCD5E96-98C6-48F3-8FB2-52EC531A563AQ41584686-0F8E4461-3B8B-431A-8B82-5DC81AC136CE
P2860
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@ast
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@en
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@nl
type
label
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@ast
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@en
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@nl
prefLabel
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@ast
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@en
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@nl
P2093
P3181
P356
P1433
P1476
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
@en
P2093
P2888
P304
P3181
P356
10.1038/ONC.2008.191
P407
P577
2008-10-02T00:00:00Z
P5875
P6179
1015205125